FI871137A0 - Tiazepinfoereningar. - Google Patents

Tiazepinfoereningar.

Info

Publication number
FI871137A0
FI871137A0 FI871137A FI871137A FI871137A0 FI 871137 A0 FI871137 A0 FI 871137A0 FI 871137 A FI871137 A FI 871137A FI 871137 A FI871137 A FI 871137A FI 871137 A0 FI871137 A0 FI 871137A0
Authority
FI
Finland
Prior art keywords
tiazepinfoereningar
Prior art date
Application number
FI871137A
Other languages
English (en)
Other versions
FI871137A (fi
FI86059C (fi
FI86059B (fi
Inventor
Edward John Warawa
Bernard Martin Migler
Original Assignee
Ici America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI871137(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici America Inc filed Critical Ici America Inc
Publication of FI871137A0 publication Critical patent/FI871137A0/fi
Publication of FI871137A publication Critical patent/FI871137A/fi
Application granted granted Critical
Publication of FI86059B publication Critical patent/FI86059B/fi
Publication of FI86059C publication Critical patent/FI86059C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI871137A 1986-03-27 1987-03-16 Foerfarande foer framstaellning av ett nytt antidopaminergiskt aktivt dibensotiazepin. FI86059C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8607684 1986-03-27
GB868607684A GB8607684D0 (en) 1986-03-27 1986-03-27 Thiazepine compounds

Publications (4)

Publication Number Publication Date
FI871137A0 true FI871137A0 (fi) 1987-03-16
FI871137A FI871137A (fi) 1987-09-28
FI86059B FI86059B (fi) 1992-03-31
FI86059C FI86059C (fi) 1992-07-10

Family

ID=10595359

Family Applications (1)

Application Number Title Priority Date Filing Date
FI871137A FI86059C (fi) 1986-03-27 1987-03-16 Foerfarande foer framstaellning av ett nytt antidopaminergiskt aktivt dibensotiazepin.

Country Status (31)

Country Link
US (1) US4879288A (fi)
EP (1) EP0240228B1 (fi)
JP (1) JPH064606B2 (fi)
KR (1) KR900001868B1 (fi)
AR (1) AR242198A1 (fi)
AT (1) ATE58132T1 (fi)
AU (1) AU593336B2 (fi)
BG (1) BG61365B2 (fi)
CA (1) CA1288428C (fi)
CY (2) CY1706A (fi)
DD (1) DD259403A5 (fi)
DE (3) DE3765969D1 (fi)
DK (1) DK174618B1 (fi)
ES (1) ES2019379T4 (fi)
FI (1) FI86059C (fi)
GB (2) GB8607684D0 (fi)
GR (1) GR3001061T3 (fi)
HK (1) HK85393A (fi)
HU (1) HU201062B (fi)
IE (1) IE59864B1 (fi)
IL (1) IL81923A (fi)
LU (1) LU90593I2 (fi)
MW (1) MW2087A1 (fi)
NL (1) NL980022I2 (fi)
NO (2) NO168771C (fi)
NZ (1) NZ219788A (fi)
PH (1) PH26516A (fi)
PT (1) PT84569B (fi)
ZA (1) ZA871940B (fi)
ZM (1) ZM2987A1 (fi)
ZW (1) ZW5787A1 (fi)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
DE3827447A1 (de) * 1988-08-12 1990-04-26 Basf Ag Polyazofarbstoffe und deren zwischenprodukte
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
WO1997035584A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9716161D0 (en) * 1997-08-01 1997-10-08 Zeneca Ltd Process
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
ATE347364T1 (de) * 2000-12-20 2006-12-15 Astrazeneca Ab Quetiapin zur behandlung der dyskinesie in nicht- psychotischen patienten
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
ES2284830T3 (es) 2001-02-06 2007-11-16 Astrazeneca Ab Uso de quetiapina para el tratamiento de la cocaina.
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
CA2468972A1 (en) * 2001-12-10 2003-07-03 Novartis Ag Methods of treating psychosis and schizophrenia based on a polymorphism in the cntf gene
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
WO2003080065A1 (en) * 2002-03-20 2003-10-02 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
KR100707050B1 (ko) 2002-11-28 2007-04-13 에스케이 주식회사 10Ｈ-디벤조[ｂ,ｆ][1,4]티아제핀-11-온의 제조방법
AU2004206827A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
WO2004076431A1 (en) * 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
WO2004078735A1 (en) * 2003-03-03 2004-09-16 Hetero Drugs Limited Novel polymorphs of quetiapine fumarate
WO2004089957A1 (en) * 2003-04-07 2004-10-21 Hetero Drugs Limited A novel crystalline form of dorzolamide hydrochloride
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
AU2004253334A1 (en) * 2003-07-02 2005-01-13 Astrazeneca Ab Metabolite of quetiapine
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
ES2223294B2 (es) * 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20050080072A1 (en) * 2003-09-01 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a thiazepine derivative
DE602004031129D1 (de) 2003-09-23 2011-03-03 Fermion Oy Verfahren zur herstellung von quetiapin
CN101005829A (zh) * 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CN101962369A (zh) 2003-12-22 2011-02-02 阿卡蒂亚药品公司 氨基取代的二芳基[a,d]环庚烯类似物作为毒蕈碱激动剂的用途及神经精神疾病的治疗方法
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR101038389B1 (ko) * 2004-06-23 2011-06-01 에스케이바이오팜 주식회사 11-(4-[2-(2-히드록시에톡시)에틸]-1-피페라지닐)-디벤조[ｂ,ｆ][1,4]티아제핀의 제조방법
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
WO2006027789A1 (en) * 2004-09-08 2006-03-16 Jubilant Organosys Limited PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20060063927A1 (en) * 2004-09-22 2006-03-23 Olga Etlin Processes for preparing quetiapine and salts thereof
WO2006035293A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Salts of quetiapine
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
WO2006077602A1 (en) * 2005-01-24 2006-07-27 Ipca Laboratories Limited INDUSTRIAL PREPARATION OF 11-[4-{2-(2-HYDROXYETHOXY ETHYL}-1-PIPERAZINYL] DIBENZO [b,f]-1[1, 4] THIAZEPINE
EA200701591A1 (ru) * 2005-01-26 2008-02-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением, содержащие антипсихотическое средство
ES2234447B1 (es) * 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
US20060211686A1 (en) * 2005-03-18 2006-09-21 Abbott Laboratories Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
US7488821B2 (en) * 2005-04-04 2009-02-10 Divi's Laboratories Limited Polymorph of Quetiapine fumarate and a process for its preparation
JP2008502707A (ja) * 2005-04-14 2008-01-31 テバ ファーマシューティカル インダストリーズ リミティド クエチアピンフマレートの調製方法
CA2605473C (en) 2005-04-21 2013-10-29 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
AU2006239900A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
CA2609185A1 (en) * 2005-05-20 2006-11-30 Ahmed F. Abdel-Magid Process for preparation of sulfamide derivatives
US20070072840A1 (en) * 2005-05-30 2007-03-29 Pandya Bhargav Polymorphic forms of quetiapine
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
GB0516603D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists
WO2007036599A1 (en) 2005-09-30 2007-04-05 Fermion Oy New crystallization process of quetiapine hemifumarate
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
WO2008079838A1 (en) * 2006-12-20 2008-07-03 Astrazeneca Ab Compounds and uses thereof
WO2009151393A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
WO2009151392A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
EP1976487A2 (en) * 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
WO2007102074A2 (en) * 2006-03-07 2007-09-13 Cadila Healthcare Limited Salts of quetiapine
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CZ300451B6 (cs) * 2006-07-03 2009-05-20 Farmak, A. S. Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
CA2704279C (en) * 2006-11-03 2014-09-30 University Of Saskatchewan Method of treating demyelination diseases
HUE032743T2 (en) 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism
EP2124908A4 (en) * 2006-12-20 2011-04-27 Astrazeneca Ab CONNECTIONS AND ITS USE
WO2008110337A2 (en) 2007-03-09 2008-09-18 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
CN100569761C (zh) * 2007-04-18 2009-12-16 湖南洞庭药业股份有限公司 制备药物纯富马酸喹硫平的生产方法
WO2009004480A2 (en) * 2007-05-07 2009-01-08 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
US20080287418A1 (en) 2007-05-16 2008-11-20 Astrazeneca Ab Extended Release Compositions and Methods for Their Manufacture
HU230144B1 (hu) * 2007-06-12 2015-09-28 Richter Gedeon Nyrt. Eljárás quetiapin előállítására
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
WO2009095529A1 (en) * 2008-01-31 2009-08-06 Fermion Oy A process for the preparation of quetiapine
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090264408A1 (en) * 2008-04-17 2009-10-22 Gulati Inder Extended release dosage forms of quetiapine
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
PE20110029A1 (es) * 2008-06-20 2011-02-11 Astrazeneca Ab Derivados de dibenzotiazepina
MX2011000090A (es) 2008-06-23 2011-03-02 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida.
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
US8440223B2 (en) * 2008-07-01 2013-05-14 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine in non-gellable polymers
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2008359725A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
DK2262486T3 (da) 2008-08-01 2013-03-25 Krka Tovarna Zdravil D D Novo Mesto Quetiapin sammensætning
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
JP2012502915A (ja) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド てんかんを治療する組成物及び方法
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
JP2012519683A (ja) 2009-03-04 2012-08-30 ランバクシー ラボラトリーズ リミテッド フマル酸クエチアピンの調製方法
EP2233130A1 (en) 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
CA2889457C (en) 2009-12-31 2016-06-28 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
TR201900067T4 (tr) 2010-03-11 2019-02-21 Kempharm Inc Ketiyapinin yağ asidi konjugatları, bunların yapılmasına ve kullanılmasına yönelik proses.
HUE041981T2 (hu) 2010-08-23 2019-06-28 Alkermes Pharma Ireland Ltd Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
WO2012064349A1 (en) 2010-11-09 2012-05-18 Forest Carl A Sleep aid composition and method
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
WO2013074048A2 (en) 2011-08-08 2013-05-23 Mahmut Bilgic Tablet forms comprising quetiapine fumarate
CN102391208A (zh) * 2011-10-25 2012-03-28 湖南洞庭药业股份有限公司 富马酸喹硫平的新晶形i及其制备方法
WO2013095312A1 (en) 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprising quetiapine fumarate
WO2013100879A1 (en) 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical compositions comprising quetiapine
US20150018362A1 (en) 2012-02-27 2015-01-15 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN104016945B (zh) * 2014-05-27 2016-06-29 渭南畅通药化科技有限公司 一种半富马酸喹硫平的制备方法
CA2990004C (en) 2015-06-19 2024-04-23 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EA202190076A1 (ru) 2018-06-19 2021-09-22 Эйджинбайо, Инк. Производные бензодиазепина, композиции и способы лечения когнитивных нарушений
WO2020025579A1 (en) 2018-07-31 2020-02-06 Medichem, S.A. Solid dosage form of quetiapine fumarate
EP4213817A1 (en) 2020-09-21 2023-07-26 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
CN113698363A (zh) * 2021-09-15 2021-11-26 苏州敬业医药化工有限公司 一种11-哌嗪-二苯并[b,f][1,4]硫氮杂卓盐酸盐的纯化方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
FR127F (fi) * 1964-03-27
FR90378E (fi) * 1965-03-26 1968-02-14
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
CH539044A (de) * 1967-10-06 1973-08-31 Gnii Orch Poluproduktov I Kras Verfahren zur Herstellung quaternärer Ammoniumsalze von 1,3-Bis-(aminomethyl)-imidazolidonen
GB1262509A (en) * 1969-06-20 1972-02-02 Science Union & Cie New tricyclic derivatives and process for their preparation
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
BE792426A (fr) * 1971-12-09 1973-06-07 Wander Ag Dr A Nouveaux derives de la dibenzo(b,f)(1,4)thiazepine, leur preparation etleur application comme medicaments
CH569730A5 (fi) * 1972-04-04 1975-11-28 Wander Ag Dr A
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH624682A5 (fi) * 1976-11-10 1981-08-14 Sandoz Ag
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines

Also Published As

Publication number Publication date
DK158587A (da) 1987-09-28
ZW5787A1 (en) 1988-11-02
IL81923A (en) 1991-03-10
HK85393A (en) 1993-08-27
FI871137A (fi) 1987-09-28
EP0240228B1 (en) 1990-11-07
FI86059C (fi) 1992-07-10
DE10075016I2 (de) 2002-10-10
DD259403A5 (de) 1988-08-24
DK174618B1 (da) 2003-07-21
HUT47568A (en) 1989-03-28
KR870008879A (ko) 1987-10-21
ATE58132T1 (de) 1990-11-15
NL980022I1 (nl) 1998-10-01
BG61365B2 (bg) 1997-06-30
GB8607684D0 (en) 1986-04-30
IE59864B1 (en) 1994-04-20
EP0240228A1 (en) 1987-10-07
PH26516A (en) 1992-08-07
KR900001868B1 (ko) 1990-03-26
CY98045I2 (el) 2010-07-28
JPS638378A (ja) 1988-01-14
CY1706A (en) 1994-01-14
GR3001061T3 (en) 1992-03-20
PT84569A (en) 1987-04-01
NZ219788A (en) 1990-02-26
AU593336B2 (en) 1990-02-08
CY98045I1 (el) 2010-07-28
JPH064606B2 (ja) 1994-01-19
NO871267L (no) 1987-09-28
MW2087A1 (en) 1987-11-11
NO168771C (no) 1992-04-01
LU90593I2 (fr) 2000-08-07
NL980022I2 (nl) 1998-11-02
IE870700L (en) 1987-09-27
ES2019379B3 (es) 1991-06-16
NO871267D0 (no) 1987-03-26
ZM2987A1 (en) 1991-02-28
PT84569B (pt) 1989-11-30
ES2019379T4 (es) 2015-08-12
ZA871940B (en) 1987-11-25
AR242198A1 (es) 1993-03-31
NO168771B (no) 1991-12-23
AU7045987A (en) 1987-10-01
NO2001009I1 (no) 2001-06-25
DK158587D0 (da) 1987-03-27
CA1288428C (en) 1991-09-03
IL81923A0 (en) 1987-10-20
GB8706949D0 (en) 1987-04-29
DE3765969D1 (en) 1990-12-13
US4879288A (en) 1989-11-07
HU201062B (en) 1990-09-28
DE10075017I1 (de) 2000-09-21
FI86059B (fi) 1992-03-31

Similar Documents

Publication Publication Date Title
ATE70057T1 (de) Antitumormittel.
DE3775679D1 (de) Vernebler.
DE3767169D1 (de) Sportschuh.
ES2019949B3 (es) Propanaminas 3-ariloxi-3-sustituidas.
FI871137A (fi) Tiazepinfoereningar.
DE3764043D1 (de) Alkylendiamine.
ATE63533T1 (de) Xylolisomerisierung.
DE3779761D1 (de) Abseilgeraet.
DE3771918D1 (de) Chinolinamide.
DE3785294D1 (de) Neigungsmesser.
DE3786679D1 (de) Schmitt-triggerschaltung.
DE3773636D1 (de) Saeurebeschleunigte hydrocarboxilierung.
DE3771271D1 (de) Fluorphthalimide.
FI860054A (fi) Motionsanordning.
DE3779382D1 (de) 3-6-diphenylpyridazine.
DE3763648D1 (de) Rollski.
FI860046A0 (fi) Foerlaengningsanordning foer traefaner.
DE3766410D1 (de) Methylalkylcyclosiloxane.
DE3669032D1 (de) Okulopressionsgeraet.
DE3770459D1 (de) 3-halogensuccinimide.
DE3764485D1 (de) Polyglycidylamine.
FI860072A0 (fi) Mataranordning foer en spannmaolstork.
FI851776L (fi) Elkandelaber.
FI77951B (fi) Foergreningsklaemma foer en sektorformig stomledare.
FI73944B (fi) Rullningsanordning foer pappersbana.

Legal Events

Date Code Title Description
TC Name/ company changed in patent

Owner name: ZENECA INC.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L171

Extension date: 20120315

FG Patent granted

Owner name: ZENECA INC.

MA Patent expired